Details of the Drug

General Information of Drug (ID: DMPZI3Q)

Drug Name
Ketoconazole
Synonyms
KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1], [2]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 531.4
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2.5-3 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-4 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
75% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The clearance of drug is 8.66 L/h [6]
Elimination
Only 2-4% of the ketoconazole dose is eliminated unchanged in the urine, and over 95% is eliminated through hepatic metabolism [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 10.7525 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 25.41 L or 0.36 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0069 mg/mL [4]
Chemical Identifiers
Formula
C26H28Cl2N4O4
IUPAC Name
1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
Canonical SMILES
CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
InChI
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1
InChIKey
XMAYWYJOQHXEEK-OZXSUGGESA-N
Cross-matching ID
PubChem CID
456201
ChEBI ID
CHEBI:48336
CAS Number
65277-42-1
DrugBank ID
DB01026
TTD ID
D0B4IF
VARIDT ID
DR00594
INTEDE ID
DR0906
ACDINA ID
D00342

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ketoconazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ketoconazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [33]
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [34]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Ketoconazole caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [35]
Ivosidenib DM8S6T7 Major Decreased metabolism of Ketoconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [36]
Midostaurin DMI6E0R Major Decreased metabolism of Ketoconazole caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [37]
Idarubicin DMM0XGL Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [38]
Arn-509 DMT81LZ Moderate Increased metabolism of Ketoconazole caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Ketoconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [40]
Oliceridine DM6MDCF Major Decreased metabolism of Ketoconazole caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [41]
Ivabradine DM0L594 Major Decreased metabolism of Ketoconazole caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [33]
Dronedarone DMA8FS5 Major Decreased metabolism of Ketoconazole caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [33]
Nifedipine DMSVOZT Moderate Decreased metabolism of Ketoconazole caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [42]
Bedaquiline DM3906J Major Decreased metabolism of Ketoconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [43]
Cilostazol DMZMSCT Major Decreased metabolism of Ketoconazole caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [39]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Posaconazole. Aspergillosis [1F20] [44]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Levalbuterol. Asthma [CA23] [45]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Pirbuterol. Asthma [CA23] [46]
Budesonide DMJIBAW Major Decreased metabolism of Ketoconazole caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [47]
Aminophylline DML2NIB Minor Altered absorption of Ketoconazole caused by Aminophylline. Asthma [CA23] [48]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Ketoconazole caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [49]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [39]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Desipramine. Attention deficit hyperactivity disorder [6A05] [44]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Ofloxacin. Bacterial infection [1A00-1C4Z] [50]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Ketoconazole caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [51]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Clarithromycin. Bacterial infection [1A00-1C4Z] [44]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Gemifloxacin. Bacterial infection [1A00-1C4Z] [50]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Norfloxacin. Bacterial infection [1A00-1C4Z] [50]
Rabeprazole DMMZXIW Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [52]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Levofloxacin. Bacterial infection [1A00-1C4Z] [50]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Retigabine. Behcet disease [4A62] [44]
Cariprazine DMJYDVK Major Decreased metabolism of Ketoconazole caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [53]
Erdafitinib DMI782S Major Decreased metabolism of Ketoconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [54]
Pexidartinib DMS2J0Z Major Decreased metabolism of Ketoconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [55]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Eribulin. Breast cancer [2C60-2C6Y] [44]
Talazoparib DM1KS78 Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [39]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Ketoconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Lapatinib DM3BH1Y Major Decreased metabolism of Ketoconazole caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
HKI-272 DM6QOVN Major Decreased metabolism of Ketoconazole caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
LY2835219 DM93VBZ Major Decreased metabolism of Ketoconazole caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [58]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Ketoconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Tucatinib DMBESUA Moderate Decreased metabolism of Ketoconazole caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Palbociclib DMD7L94 Major Decreased metabolism of Ketoconazole caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Ketoconazole caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Ketoconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Major Decreased metabolism of Ketoconazole caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Atorvastatin DMF28YC Major Decreased metabolism of Ketoconazole caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [62]
Macitentan DMP79A1 Major Decreased metabolism of Ketoconazole caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [63]
PF-04449913 DMSB068 Major Decreased metabolism of Ketoconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [64]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Olodaterol. Chronic obstructive pulmonary disease [CA22] [46]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Ketoconazole caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [65]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Indacaterol. Chronic obstructive pulmonary disease [CA22] [46]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Arformoterol. Chronic obstructive pulmonary disease [CA22] [46]
Levomilnacipran DMV26S8 Major Decreased metabolism of Ketoconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [66]
Fidaxomicin DMFP6MV Minor Decreased clearance of Ketoconazole due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [67]
Anisindione DM2C48U Moderate Decreased metabolism of Ketoconazole caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [34]
Regorafenib DMHSY1I Moderate Decreased metabolism of Ketoconazole caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [33]
Intedanib DMSTA36 Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [68]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Isoproterenol. Conduction disorder [BC63] [45]
Drospirenone DM1A9W3 Major Decreased metabolism of Ketoconazole caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [33]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Ketoconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [59]
Ulipristal DMBNI20 Minor Decreased metabolism of Ketoconazole caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [39]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Halothane. Corneal disease [9A76-9A78] [44]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Sevoflurane. Corneal disease [9A76-9A78] [44]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Probucol. Coronary atherosclerosis [BA80] [44]
Oxtriphylline DMLHSE3 Minor Altered absorption of Ketoconazole caused by Oxtriphylline. Cough [MD12] [48]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Ketoconazole and Pasireotide. Cushing syndrome [5A70] [44]
Osilodrostat DMIJC9X Major Decreased metabolism of Ketoconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [39]
Ivacaftor DMZC1HS Major Decreased metabolism of Ketoconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [33]
Rivaroxaban DMQMBZ1 Major Decreased clearance of Ketoconazole due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [33]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Sertraline. Depression [6A70-6A7Z] [44]
Vilazodone DM4LECQ Major Decreased metabolism of Ketoconazole caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [69]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Ketoconazole caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Ketoconazole and Escitalopram. Depression [6A70-6A7Z] [44]
OPC-34712 DMHG57U Major Decreased metabolism of Ketoconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [71]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Clomipramine. Depression [6A70-6A7Z] [44]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Doxepin. Depression [6A70-6A7Z] [44]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Ketoconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [72]
Mepenzolate DM8YU2F Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Mepenzolate. Digestive system disease [DE2Z] [73]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Ketoconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [74]
Oxybutynine DMJPBAX Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Oxybutynine. Discovery agent [N.A.] [73]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [44]
Ospemifene DMC4GEI Moderate Decreased metabolism of Ketoconazole caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [75]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Ketoconazole and Deutetrabenazine. Dystonic disorder [8A02] [76]
Ingrezza DMVPLNC Major Decreased metabolism of Ketoconazole caused by Ingrezza mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [77]
Cenobamate DMGOVHA Moderate Increased metabolism of Ketoconazole caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [78]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ketoconazole caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Ketoconazole caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Ketoconazole caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Lacosamide DMVM6QR Moderate Decreased metabolism of Ketoconazole caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Phenobarbital DMXZOCG Moderate Increased metabolism of Ketoconazole caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Cannabidiol DM0659E Minor Decreased metabolism of Ketoconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [39]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Ketoconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [79]
Tazemetostat DMWP1BH Major Decreased metabolism of Ketoconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [80]
Solifenacin DMG592Q Major Decreased metabolism of Ketoconazole caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [33]
Mirabegron DMS1GYT Minor Decreased metabolism of Ketoconazole caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [81]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Ketoconazole caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [82]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [52]
Ripretinib DM958QB Major Decreased metabolism of Ketoconazole caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [33]
Sunitinib DMCBJSR Moderate Decreased metabolism of Ketoconazole caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [33]
Avapritinib DMK2GZX Major Decreased metabolism of Ketoconazole caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [39]
Colchicine DM2POTE Major Decreased metabolism of Ketoconazole caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [83]
Boceprevir DMBSHMF Moderate Decreased metabolism of Ketoconazole caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
Simeprevir DMLUA9D Major Decreased metabolism of Ketoconazole caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [33]
Daclatasvir DMSFK9V Major Decreased metabolism of Ketoconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [39]
Rifampin DMA8J1G Major Increased metabolism of Ketoconazole caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Rifapentine DMCHV4I Major Increased metabolism of Ketoconazole caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [85]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Ketoconazole and Brentuximab vedotin. Hodgkin lymphoma [2B30] [86]
MK-1439 DM215WE Minor Decreased metabolism of Ketoconazole caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Ketoconazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [89]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Ketoconazole caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [90]
Dolutegravir DMCZGRE Minor Decreased metabolism of Ketoconazole caused by Dolutegravir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [91]
Etravirine DMGV8QU Moderate Increased metabolism of Ketoconazole caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Ketoconazole caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [93]
Darunavir DMN3GCH Moderate Decreased metabolism of Ketoconazole caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Atazanavir DMSYRBX Moderate Decreased metabolism of Ketoconazole caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Maraviroc DMTL94F Major Decreased metabolism of Ketoconazole caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [95]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Ketoconazole and Teriflunomide. Hyper-lipoproteinaemia [5C80] [44]
BMS-201038 DMQTAGO Major Decreased metabolism of Ketoconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [33]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [39]
Aliskiren DM1BV7W Moderate Decreased metabolism of Ketoconazole caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [44]
Levamlodipine DM92S6N Moderate Decreased metabolism of Ketoconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [42]
Tolvaptan DMIWFRL Major Decreased metabolism of Ketoconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [33]
Retapamulin DM9JXB7 Minor Decreased metabolism of Ketoconazole caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [96]
Belladonna DM2RBWK Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Belladonna. Infectious gastroenteritis/colitis [1A40] [73]
TP-434 DM5A31S Minor Decreased metabolism of Ketoconazole caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [97]
Berotralstat DMWA2DZ Major Decreased clearance of Ketoconazole due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [98]
Suvorexant DM0E6S3 Major Decreased metabolism of Ketoconazole caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [33]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Ketoconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [99]
ITI-007 DMUQ1DO Major Decreased metabolism of Ketoconazole caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [100]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Polyethylene glycol. Irritable bowel syndrome [DD91] [39]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Phenolphthalein. Irritable bowel syndrome [DD91] [44]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Ketoconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [101]
Naloxegol DML0B41 Major Decreased metabolism of Ketoconazole caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [33]
Pemigatinib DM819JF Major Decreased metabolism of Ketoconazole caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [39]
Crizotinib DM4F29C Major Decreased metabolism of Ketoconazole caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
Brigatinib DM7W94S Major Decreased metabolism of Ketoconazole caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
Ceritinib DMB920Z Major Decreased metabolism of Ketoconazole caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Ketoconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [103]
PF-06463922 DMKM7EW Major Decreased metabolism of Ketoconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [104]
Osimertinib DMRJLAT Major Decreased metabolism of Ketoconazole caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [105]
Pralsetinib DMWU0I2 Major Decreased metabolism of Ketoconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [106]
Capmatinib DMYCXKL Major Decreased metabolism of Ketoconazole caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [107]
Selpercatinib DMZR15V Major Decreased metabolism of Ketoconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [39]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Ketoconazole and Halofantrine. Malaria [1F40-1F45] [108]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Ketoconazole and Hydroxychloroquine. Malaria [1F40-1F45] [109]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Primaquine. Malaria [1F40-1F45] [44]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [39]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ketoconazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [110]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ketoconazole and Idelalisib. Mature B-cell leukaemia [2A82] [111]
GDC-0199 DMH0QKA Major Decreased metabolism of Ketoconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [112]
IPI-145 DMWA24P Major Decreased metabolism of Ketoconazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [113]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Ketoconazole and Arsenic trioxide. Mature B-cell lymphoma [2A85] [114]
Acalabrutinib DM7GCVW Major Decreased metabolism of Ketoconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [115]
Ibrutinib DMHZCPO Major Decreased metabolism of Ketoconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [33]
Ponatinib DMYGJQO Major Decreased metabolism of Ketoconazole caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [33]
Arry-162 DM1P6FR Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by Arry-162. Melanoma [2C30] [33]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Ketoconazole and Vemurafenib. Melanoma [2C30] [44]
Selumetinib DMC7W6R Major Decreased metabolism of Ketoconazole caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [116]
LGX818 DMNQXV8 Major Decreased metabolism of Ketoconazole caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [117]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Ketoconazole caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [33]
Rimegepant DMHOAUG Moderate Decreased metabolism of Ketoconazole caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [118]
Exjade DMHPRWG Moderate Decreased metabolism of Ketoconazole caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [119]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Ketoconazole due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [44]
Flibanserin DM70DTN Major Decreased metabolism of Ketoconazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [120]
Panobinostat DM58WKG Major Decreased metabolism of Ketoconazole caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [121]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Thalidomide. Multiple myeloma [2A83] [33]
Siponimod DM2R86O Major Decreased metabolism of Ketoconazole caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [33]
Fingolimod DM5JVAN Moderate Decreased metabolism of Ketoconazole caused by Fingolimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [122]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Ketoconazole and Ozanimod. Multiple sclerosis [8A40] [123]
Deflazacort DMV0RNS Major Decreased metabolism of Ketoconazole caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [39]
Romidepsin DMT5GNL Moderate Decreased metabolism of Ketoconazole caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [124]
Fedratinib DM4ZBK6 Major Decreased metabolism of Ketoconazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [39]
Nilotinib DM7HXWT Major Decreased metabolism of Ketoconazole caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Ruxolitinib DM7Q98D Major Decreased metabolism of Ketoconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [125]
Dasatinib DMJV2EK Major Decreased metabolism of Ketoconazole caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Vorapaxar DMA16BR Major Decreased metabolism of Ketoconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [33]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Promethazine. Nausea/vomiting [MD90] [44]
E-2007 DMJDYNQ Minor Decreased metabolism of Ketoconazole caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [39]
Entrectinib DMMPTLH Major Decreased metabolism of Ketoconazole caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [33]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Ketoconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [126]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Lofexidine. Opioid use disorder [6C43] [44]
S-297995 DM26IH8 Moderate Decreased metabolism of Ketoconazole caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [39]
Olaparib DM8QB1D Major Decreased metabolism of Ketoconazole caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [33]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Rucaparib. Ovarian cancer [2C73] [44]
MK-4827 DMLYGH4 Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [127]
Flavoxate DMKV4NL Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Flavoxate. Pain [MG30-MG3Z] [73]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Triclabendazole. Parasitic worm infestation [1F90] [44]
Istradefylline DM20VSK Major Decreased metabolism of Ketoconazole caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [128]
Pimavanserin DMR7IVC Major Decreased metabolism of Ketoconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [129]
Abametapir DM2RX0I Moderate Decreased metabolism of Ketoconazole caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [130]
Methylscopolamine DM5VWOB Moderate Decreased absorption of Ketoconazole due to altered gastric pH caused by Methylscopolamine. Peptic ulcer [DA61] [73]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ketoconazole and Macimorelin. Pituitary gland disorder [5A60-5A61] [131]
Lefamulin DME6G97 Major Decreased metabolism of Ketoconazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [132]
Ergonovine DM0VEC1 Major Decreased metabolism of Ketoconazole caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [133]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Ketoconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [134]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Degarelix. Prostate cancer [2C82] [39]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and ABIRATERONE. Prostate cancer [2C82] [39]
Enzalutamide DMGL19D Moderate Increased metabolism of Ketoconazole caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [135]
Darolutamide DMV7YFT Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [136]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Bicalutamide. Prostate cancer [2C82] [39]
Silodosin DMJSBT6 Major Decreased metabolism of Ketoconazole caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [33]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Ketoconazole caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [137]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Levomepromazine. Psychotic disorder [6A20-6A25] [44]
Ambrisentan DMD1QXW Minor Decreased metabolism of Ketoconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [138]
Riociguat DMXBLMP Major Decreased metabolism of Ketoconazole caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [33]
Everolimus DM8X2EH Major Decreased metabolism of Ketoconazole caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [33]
Axitinib DMGVH6N Major Decreased metabolism of Ketoconazole caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [33]
Temsirolimus DMS104F Major Increased metabolism of Ketoconazole caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [33]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Ketoconazole and Gatifloxacin. Respiratory infection [CA07-CA4Z] [139]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Ketoconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [140]
Upadacitinib DM32B5U Major Decreased metabolism of Ketoconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [141]
Tofacitinib DMBS370 Major Decreased metabolism of Ketoconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [33]
Dexamethasone DMMWZET Moderate Decreased metabolism of Ketoconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [140]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Ketoconazole and Leflunomide. Rheumatoid arthritis [FA20] [44]
Quetiapine DM1N62C Major Decreased metabolism of Ketoconazole caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [142]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Ketoconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [143]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Ketoconazole and Iloperidone. Schizophrenia [6A20] [44]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Paliperidone. Schizophrenia [6A20] [44]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Ketoconazole and Amisulpride. Schizophrenia [6A20] [33]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Asenapine. Schizophrenia [6A20] [44]
Pimozide DMW83TP Major Decreased metabolism of Ketoconazole caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [33]
Avanafil DM75CXN Major Decreased metabolism of Ketoconazole caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [33]
Voxelotor DMCS6M5 Major Decreased metabolism of Ketoconazole caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [144]
LDE225 DMM9F25 Major Decreased metabolism of Ketoconazole caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [145]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ketoconazole caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [39]
Larotrectinib DM26CQR Major Decreased metabolism of Ketoconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
Docetaxel DMDI269 Major Decreased clearance of Ketoconazole due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [146]
Trabectedin DMG3Y89 Major Decreased metabolism of Ketoconazole caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
Armodafinil DMGB035 Minor Decreased metabolism of Ketoconazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
LEE011 DMMX75K Major Decreased metabolism of Ketoconazole caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [147]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Ketoconazole and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [44]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [39]
Taxol DMUOT9V Moderate Decreased metabolism of Ketoconazole caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Pitolisant DM8RFNJ Moderate Increased metabolism of Ketoconazole caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [39]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [44]
Pomalidomide DMTGBAX Moderate Decreased clearance of Ketoconazole due to the transporter inhibition by Pomalidomide. Systemic sclerosis [4A42] [33]
Fostamatinib DM6AUHV Major Decreased metabolism of Ketoconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [149]
As-1670542 DMV05SW Moderate Decreased metabolism of Ketoconazole caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [39]
Apixaban DM89JLN Major Decreased metabolism of Ketoconazole caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [33]
Brilinta DMBR01X Major Decreased metabolism of Ketoconazole caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [33]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Lenvatinib. Thyroid cancer [2D10] [44]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Ketoconazole and Papaverine. Tonus and reflex abnormality [MB47] [150]
Trimetrexate DMDEA85 Minor Decreased metabolism of Ketoconazole caused by Trimetrexate mediated inhibition of CYP450 enzyme. Toxoplasmosis [1F57] [151]
Saxagliptin DMGXENV Moderate Decreased metabolism of Ketoconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [39]
Elagolix DMB2C0E Major Decreased metabolism of Ketoconazole caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [152]
Fluticasone DMGCSVF Major Decreased metabolism of Ketoconazole caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [153]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Ketoconazole and Procainamide. Ventricular tachyarrhythmia [BC71] [44]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Propafenone. Ventricular tachyarrhythmia [BC71] [44]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Ketoconazole and Flecainide. Ventricular tachyarrhythmia [BC71] [44]
Amiodarone DMUTEX3 Major Decreased metabolism of Ketoconazole caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [154]
⏷ Show the Full List of 251 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ketoconazole 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2568).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075273.
3 Daneshmend TK, Warnock DW: Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988 Jan;14(1):13-34. doi: 10.2165/00003088-198814010-00002.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343-73.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
21 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
22 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
27 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
28 Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
29 Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
30 Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
31 Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
32 Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
33 Cerner Multum, Inc. "Australian Product Information.".
34 Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
35 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
36 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
37 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
38 Multum Information Services, Inc. Expert Review Panel.
39 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
41 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
42 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
43 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
44 Canadian Pharmacists Association.
45 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
46 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
47 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
48 Brown MW, Maldonado AL, Meredith CG, Speeg KV "Effect of ketoconazole on hepatic oxidative drug metabolism." Clin Pharmacol Ther 37 (1985): 290-7. [PMID: 3971653]
49 Lahu G, Huennemeyer A, von Richter O, et al. "Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-Oxide." J Clin Pharmacol 48 (2008): 1339-49. [PMID: 18757786]
50 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
51 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
52 Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
53 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
54 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
55 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
56 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
57 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
58 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
59 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
60 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
61 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
63 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
64 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
65 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
66 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
67 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
68 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
69 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
70 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
71 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
72 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
73 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
74 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
75 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
76 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
77 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
78 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
79 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
80 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
81 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
82 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
83 Colchicine: serious interactions. Prescrire Int 17 (2008): 151-3. [PMID: 19492485]
84 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
85 Abadie-Kemmerly S, Pankey GA, Dalvisio JR "Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin." Ann Intern Med 109 (1988): 844-5. [PMID: 3190036]
86 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
87 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
88 Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
89 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
90 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
91 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
92 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
93 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
94 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
95 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
96 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
97 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
98 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
99 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
100 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
101 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
102 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
103 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
104 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
105 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
106 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
107 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
108 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
109 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
110 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
111 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
112 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
113 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
114 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
115 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
116 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
117 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
118 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
119 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
120 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
121 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
122 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
123 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
124 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
125 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
126 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
127 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
128 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
129 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
130 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
131 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
132 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
133 Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
134 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
135 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
136 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
137 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
138 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
139 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
140 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
141 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
142 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
143 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
144 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
145 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
146 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
147 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
148 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
149 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
150 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
151 Product Information. Neutrexin (trimetrexate). US Bioscience, West Conshohocken, PA.
152 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
153 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
154 Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]